Compare MCY & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MCY | IRTC |
|---|---|---|
| Founded | 1961 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 4.8B |
| IPO Year | 1995 | 2016 |
| Metric | MCY | IRTC |
|---|---|---|
| Price | $90.58 | $123.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | $100.00 | ★ $209.69 |
| AVG Volume (30 Days) | 319.1K | ★ 676.3K |
| Earning Date | 05-20-2026 | 05-25-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | 15.62 | ★ 61.71 |
| EPS | ★ 9.77 | N/A |
| Revenue | ★ $5,992,468,000.00 | $747,138,000.00 |
| Revenue This Year | $5.16 | $19.58 |
| Revenue Next Year | $5.59 | $15.95 |
| P/E Ratio | $9.34 | ★ N/A |
| Revenue Growth | 9.44 | ★ 26.24 |
| 52 Week Low | $47.06 | $92.52 |
| 52 Week High | $100.06 | $210.01 |
| Indicator | MCY | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 50.76 | 31.25 |
| Support Level | $84.22 | N/A |
| Resistance Level | $94.91 | $167.19 |
| Average True Range (ATR) | 3.65 | 7.93 |
| MACD | 0.24 | -1.36 |
| Stochastic Oscillator | 46.27 | 9.80 |
Mercury General Corp is an insurance holding company. It is engaged in writing personal automobile insurance and provides related property and casualty insurance products. The Company offers the following types of automobile coverage: collision, property damage, bodily injury ("BI"), comprehensive, personal injury protection ("PIP"), underinsured and uninsured motorist, and other hazards. The Company offers the following types of homeowners coverage: dwelling, liability, personal property, and other coverages.
iRhythm Holdings Inc formerly, iRhythm Technologies Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.